Acquisition by Milton Werner of 45000 shares of Inhibikase TherapeuticsInc at 2.16 subject to Rule 16b-3
| IKT Stock | USD 2.92 0.19 6.96% |
Slightly above 54% of Inhibikase Therapeutics' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Inhibikase Therapeutics suggests that some traders are interested. Inhibikase Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Inhibikase Therapeutics' earnings reports, geopolitical events, and overall market trends.
Inhibikase |
Filed transaction by Inhibikase TherapeuticsInc Director, 10 Percent Owner, Officer President And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Inhibikase Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Inhibikase Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Inhibikase Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Inhibikase Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Inhibikase Therapeutics Fundamental Analysis
We analyze Inhibikase Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibikase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibikase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Inhibikase Therapeutics is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Inhibikase Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Inhibikase Therapeutics stock to make a market-neutral strategy. Peer analysis of Inhibikase Therapeutics could also be used in its relative valuation, which is a method of valuing Inhibikase Therapeutics by comparing valuation metrics with similar companies.
Peers
Inhibikase Therapeutics Related Equities
| ANTX | AN2 Therapeutics | 21.90 | ||||
| DMAC | DiaMedica Therapeutics | 8.64 | ||||
| MCRB | Seres Therapeutics | 6.52 | ||||
| MIST | Milestone Pharmaceuticals | 6.42 | ||||
| QNRX | Quoin Pharmaceuticals | 1.69 | ||||
| PMVP | Pmv Pharmaceuticals | 1.25 | ||||
| RNXT | RenovoRx | 0.79 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
| LGVN | Longeveron LLC | 0.49 | ||||
| NTRB | Nutriband | 1.03 | ||||
| TPST | Tempest Therapeutics | 1.04 | ||||
| ONCY | Oncolytics Biotech | 2.11 | ||||
| SCPH | Scpharmaceuticals | 3.21 | ||||
| VRAX | Virax Biolabs | 4.83 |
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.